摘要
目的探讨依那普利联合阿托伐他汀治疗早期糖尿病肾病(DN)的效果。方法将90例早期DN患者随机分为对照组和观察组,各45例。对照组单用依那普利治疗,观察组给予依那普利联合阿托伐他汀治疗。结果治疗后,两组患者的空腹血糖(FBG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(Hb A1C)水平均较治疗前显著降低(P<0.05),但组间比较无显著差异(P>0.05);两组患者的总胆固醇(TC)、三酰甘油(TG)水平均较治疗前明显降低(P<0.05),高密度脂蛋白胆固醇(HDL-C)较治疗前明显增高(P<0.05),且观察组改善更显著(P<0.05);两组患者的血肌酐(SCr)、尿微量蛋白与肌酐比值(ACR)、尿β_2微球蛋白(β_2-MG)水平均较治疗前显著降低(P<0.05),且观察组降低更明显(P<0.05)。结论依那普利联合阿托伐他汀治疗早期DN,可显著降低患者血清SCr,ACR,β_2-MG水平,保护肾功能,且未明显增加药品不良反应,值得临床推广。
Objective To observe the clinical effect of enalapril combined with atorvastatin in the treatment of early diabetic nephropathy（ DN）. Methods Totally 90 patients with early DN were randomly divided into the control group and the observation group,45 cases in each group. The control group was treated with enalapril,while the observation group was treated with enalapril combined with atorvastatin. Results After treatment,the FBG,2 h PG and HbA_（1C） in the two groups were significantly decreased（ P 0. 05）,but there was no significant difference between the two groups（ P 0. 05）. After treatment,the TG and TC in the two groups were significantly decreased（ P 0. 05）,while HDL-C was significantly increased（ P 0. 05）,and the observation group improved more significantly（ P 0. 05）. After treatment,the SCr,ACR,and β_2-MG in the two groups were significantly decreased（ P 0. 05）,and the observation group decreased more significantly（ P 0. 05）. Conclusion Enalapril combined with atorvastatin in the treatment of early DN can significantly reduce the serum levels of SCr,ACR,and β_2-MG and protect renal function,without significantly increasing adverse drug reactions,it is worthy of clinical promotion.
出处
《中国药业》
CAS
2017年第16期76-78,共3页
China Pharmaceuticals
